T cell vaccination in mice with invasive pulmonary aspergillosis.
Aspergillus fumigatus, an opportunistic fungal pathogen, is responsible for multiple airway diseases of an allergic and a nonallergic nature. In a murine model of invasive pulmonary aspergillosis, resistance is associated with a decreased lung inflammatory pathology and the occurrence of an IL-12-dependent Th1-type reactivity that are both impaired by IL-4. In the present study we assess the ability of Aspergillus crude culture filtrate Ags and the recombinant allergen Asp f 2 to induce protective antifungal responses in mice with invasive pulmonary aspergillosis. Similar to what occurred upon nasal exposure to viable A. fumigatus conidia, treatment of immunocompetent mice with Aspergillus crude culture filtrate Ags resulted in the development of local and peripheral protective Th1 memory responses, mediated by Ag-specific CD4+ T cells producing IFN-gamma and IL-2 capable of conferring protection upon adoptive transfer to naive recipients. Protective Th1 responses could not be observed in mice deficient of IFN-gamma or IL-12 and did not occur in response to Asp f 2, which, on the contrary, elicited high level production of inhibitory IL-4. The results show that Ags of Aspergillus exist with the ability to induce both Th1- and Th2-type reactivity during infection, a finding that suggests a possible mechanism through which potentially protective immune responses are inhibited in mice with the infection. However, the occurrence of Th1-mediated resistance upon vaccination with Aspergillus crude culture filtrate Ags, suggests the existence of fungal Ags useful as a candidate vaccine against invasive pulmonary aspergillosis.
Cenci
E
E
Department of Experimental Medicine and Biochemical Sciences, University of Perugia, Italy.
Mencacci
A
A
Bacci
A
A
Bistoni
F
F
Kurup
V P
VP
Romani
L
L
D000281:Administration, Intranasal; D019264:Adoptive Transfer / Q000379:methods; D000818:Animals; D000908:Antibodies, Fungal / Q000096:biosynthesis; D000946:Antigens, Fungal / Q000008:administration & dosage / Q000276:immunology; D001228:Aspergillosis / Q000276:immunology* / Q000473:pathology; D001232:Aspergillus fumigatus / Q000276:immunology*; D001992:Bronchoalveolar Lavage Fluid / Q000276:immunology; D003470:Culture Media; D016207:Cytokines / Q000096:biosynthesis; D005260:Female; D005656:Fungal Proteins / Q000008:administration & dosage / Q000276:immunology; D005657:Fungal Vaccines / Q000008:administration & dosage / Q000276:immunology*; D007073:Immunoglobulin E / Q000096:biosynthesis; D008172:Lung Diseases, Fungal / Q000276:immunology* / Q000473:pathology; D008213:Lymphocyte Activation / Q000276:immunology; D008297:Male; D051379:Mice; D008807:Mice, Inbred BALB C; D018345:Mice, Knockout; D013154:Spleen / Q000166:cytology / Q000276:immunology / Q000637:transplantation; D013601:T-Lymphocytes / Q000276:immunology / Q000378:metabolism / Q000637:transplantation*; D018417:Th1 Cells / Q000166:cytology / Q000378:metabolism / Q000637:transplantation
D000908:Antibodies, Fungal; D000946:Antigens, Fungal; D003470:Culture Media; D016207:Cytokines; D005656:Fungal Proteins; D005657:Fungal Vaccines; C106810:allergen Asp f 2, Aspergillus fumigatus; D007073:Immunoglobulin E